Article
No evidence that polymorphisms in CYP2C8, CYP2C9, UGT1A6, PPARdelta and PPARgamma act as modifiers of the protective effect of regular NSAID use on the risk of colorectal carcinoma.
Pharmacogenetics and genomics - 1 Oct 2005
McGreavey Louise E, Turner Faye, Smith Gillian, Boylan Katherine, Timothy Bishop D, Forman David, Roland Wolf C, Barrett Jennifer H
Abstract excerpt
OBJECTIVES: Regular continuous non-steroidal anti-inflammatory drug (NSAID) use has been associated with a reduction in risk of colorectal cancer. Our objective was to investigate whether or not a number of the polymorphic genes involved in the metabolism of NSAIDs, including cytochrome P450 s (CYPs), act as modifiers of this protective effect. METHODS: As part of a multi-centre case-control study, 478 colorectal...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.